The decisions made at the Greater Manchester Medicines Management Group (GMMMG) October and November 2024 meetings have now been reviewed by GM Executive and can be found at https://gmmmg.nhs.uk/meetings/decision-summaries/. This includes the recommendations made by GMMMG in October and November 2024 and NICE Technology appraisals published in June and July 2024.
The following decisions were approved and can be found at:
- Updates to formulary and RAG list – https://gmmmg.nhs.uk/joint-formulary/gmmmg-formulary-chapters/ and https://gmmmg.nhs.uk/rag-category/adult/. Full details are available in the formulary change log and in the decision summaries linked above.
- Place in therapy of bempedoic acid clarified
- Brand name removed from melatonin 2mg MR tablets
- Tenecteplase for acute ischaemic stroke added as RED
- Lebrikizumab for atopic dermatitis added as RED
- Greater Manchester recommended blood glucose meters – https://gmmmg.nhs.uk/guidance/clinical-guidance-and-pathways/
Colleagues are asked disseminate for implementation within your organisations.
All approved CRG and GMMMG meeting minutes can be found at: https://gmmmg.nhs.uk/meetings/clinical-reference-group/ and https://gmmmg.nhs.uk/meetings/gmmmg-meetings/.